Follistatin Benefits: What Studies Report

Follistatin is an endogenous glycoprotein that binds and neutralises several TGF-beta superfamily ligands, most notably activin A and myostatin (GDF-8). Because myostatin restrains skeletal muscle growth, follistatin has been discussed widely as a candidate for muscle-related outcomes. The published record, however, is mostly made up of mechanism papers, biomarker studies in disease populations, and exercise-training trials that measured circulating follistatin as one of several outcomes — not trials in which follistatin itself was given to people and benefits were measured. This page organises what studies actually reported, by outcome domain, and flags where evidence is animal, in-vitro, observational or simply absent.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no finding below should be read as a promise of an outcome.

How the Evidence Is Structured

It helps to separate three very different kinds of evidence that get collapsed together when follistatin is discussed:

• Follistatin as a signalling molecule — laboratory and animal work on activin/myostatin inhibition.
• Follistatin as a biomarker — human studies that measured circulating follistatin or follistatin-like 3 (FSTL3) and related it to a disease state or to training.
• Follistatin as an administered therapy — the thinnest category in humans, and the one most relevant to claims made about injectable peptides.

Muscle Mass, Strength and Sarcopenia

The most common claim attached to follistatin is muscle growth, by analogy with myostatin blockade. The verified human literature here is about exercise, not about administered follistatin.

Resistance training trials that measured muscle growth factors

A randomised controlled trial of 16 weeks of resistance training in older adult women with sarcopenia measured muscle quality alongside muscle growth factors, and researchers reported changes in these outcomes with training (Int J Environ Res Public Health, 2021). A separate randomised controlled trial compared low-load resistance training with blood flow restriction against conventional high-intensity resistance training in older people diagnosed with sarcopenia, and the study reported outcomes for both training approaches (Sci Rep, 2024). A further randomised study compared 12 weeks of whole-body vibration training with resistance training in older people with sarcopenia (Sci Rep, 2025). These trials are relevant because they are where follistatin and related growth-factor measurements are typically nested in humans — the intervention being tested was exercise, not a peptide.

What that does and does not show

None of the above administered follistatin. They do not establish that giving follistatin to a human increases muscle mass. Readers encountering claims of dramatic lean-mass gain should note that the verified literature contains no human dosing trial of follistatin peptide, and therefore no dose, duration or magnitude of effect can be stated here. A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance examined safety and efficacy across this product category and is the most directly relevant reference point for peptides marketed to athletes (Sports Med, 2026).

Context from the anabolic-signalling literature

A review of mechanisms of testosterone's anabolic effects on muscle and function discussed controversies and newer insights into how anabolic signals act on muscle and physical function (Endocr Rev, 2026). That review is useful background for why single-pathway manipulation (such as blocking one TGF-beta ligand) does not map simply onto strength or function outcomes in humans.

Metabolic Outcomes

Follistatin is also produced by the liver and behaves as a metabolic hormone, which is where some of the strongest human association data sit. A review of follistatin and follistatin-like 3 in metabolic disorders summarised the published relationships between these proteins and metabolic disease states (Prostaglandins Other Lipid Mediat, 2023). Important nuance: association studies of a circulating protein cannot tell you the direction of causation, and a protein that rises in a disease state is not automatically a treatment for it. The review frame was the biology of these proteins in metabolic disorders, not a demonstration that administering follistatin improves metabolic endpoints in people.

Weight loss and lean-mass preservation

One recurring search theme is whether follistatin could preserve muscle during weight loss. A review of the impact of weight loss on fat-free mass, muscle, bone and haematopoiesis health discussed implications for emerging pharmacotherapies aiming at fat reduction with lean mass preservation (Metabolism, 2024). That review framed lean-mass preservation as an active research question for emerging agents; it is not a report that follistatin has been shown to do this in people.

Cardiac and Pulmonary Biology

Activin-pathway proteins have been profiled in cardiovascular and pulmonary disease, which explains why follistatin appears in those literatures.

A study profiling serum and pulmonary expression of the activin signalling system in pulmonary arterial hypertension reported expression patterns for components of that system in this population (Circulation, 2023). Separately, a study using plasma proteomics and single-cell transcriptomics to prioritise candidate proteins in post-myocardial-infarction heart failure reported candidate prioritisation from those combined datasets (Circulation, 2020). Both are discovery and profiling studies. They describe where activin-system and follistatin-family signals appear in disease; they did not test follistatin as a treatment and reported no outcomes from administering it.

Neuromuscular Disease

Myostatin-pathway inhibition has been explored in muscle-wasting disease, which is where follistatin-related gene-therapy work is sometimes cited. An update on inclusion body myositis reviewed the state of knowledge and therapeutic landscape for that condition (Curr Opin Rheumatol, 2014). The practical point for readers is that neuromuscular-disease research programmes are conducted under regulated clinical trial conditions in defined patient populations, and their design, oversight and endpoints bear no relationship to unregulated peptide use in healthy people.

Claims With Weak or Absent Support

Several benefits commonly attached to follistatin are not supported by the verified literature summarised on this page. Stated plainly:

• Specific lean-mass gains in healthy adults. No human trial in the verified set administered follistatin and measured body composition; the sarcopenia trials tested exercise interventions (Int J Environ Res Public Health, 2021).
• Fat loss as a direct effect. The metabolic literature reviewed follistatin and FSTL3 in metabolic disorders as biology, not as a fat-loss intervention (Prostaglandins Other Lipid Mediat, 2023).
• Anti-ageing or longevity outcomes. No study in the verified set reported longevity endpoints.
• Injury healing in athletes. The peptide review for musculoskeletal injuries and athletic performance addressed approved and unapproved agents and their safety and efficacy evidence base (Sports Med, 2026); absence of robust human data is the operative finding for most unapproved peptides in that category.

Adverse Events: What Studies Report

There is no human safety dataset for injectable follistatin peptides in the verified literature, and this page therefore reports no dose, no frequency of adverse events and no safety profile for such products. The closest available reference is the review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, which examined this product class and its regulatory position (Sports Med, 2026).

Two general safety considerations appear in the surrounding literature. First, activin and TGF-beta signalling is not muscle-specific: the activin system was profiled across serum and lung tissue in pulmonary arterial hypertension (Circulation, 2023), and proteomic work in post-myocardial-infarction heart failure placed related signalling in cardiac disease biology (Circulation, 2020), which means systemic manipulation of this pathway has implications beyond skeletal muscle. Second, materials sold for research use only are not manufactured, tested or labelled to the standards required of approved medicines.

Related Endocrine Context

Follistatin sits inside a broader hormonal network. A review of relative energy deficiency in sport described endocrine manifestations, pathophysiology and treatments in athletes with low energy availability (Endocr Rev, 2024), which is relevant because energy availability independently shapes the hormonal environment in which any muscle-related measurement is taken. In the supplement literature, a trial comparing creatine hydrochloride with creatine monohydrate alongside resistance training measured anabolic and catabolic hormones, strength and body composition (Physiol Res, 2024) — an example of the trial design that would be required to make any human claim about an administered agent, and which does not yet exist for follistatin peptides.

Reading Follistatin Claims Critically

1. Check who received what. If the study gave exercise and measured follistatin, it is not evidence that follistatin given as a drug does anything (Sci Rep, 2024).
2. Check the species and the system. Mechanistic and expression-profiling work in tissue or animals is labelled as such and does not transfer directly to human outcomes (Circulation, 2023).
3. Check whether a benefit was measured or inferred. Biomarker association is not an outcome (Prostaglandins Other Lipid Mediat, 2023).
4. Check for a safety dataset. A compound with published mechanism and no published human safety data is in a different evidentiary position from an approved medicine (Sports Med, 2026).

For a broader overview of what follistatin is and how it is studied, see the follistatin learn page. Again, this page is educational only and is not medical advice; decisions about any compound belong with a licensed physician.

References

• Follistatin and follistatin-like 3 in metabolic disorders (Prostaglandins & Other Lipid Mediators, 2023)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial (International Journal of Environmental Research and Public Health, 2021)
• Effectiveness of low-load resistance training with blood flow restriction vs. conventional high-intensity resistance training in older people diagnosed with sarcopenia: a randomized controlled trial (Scientific Reports, 2024)
• Effects of 12-week whole-body vibration training versus resistance training in older people with sarcopenia (Scientific Reports, 2025)
• Mechanisms of Testosterone's Anabolic Effects on Muscle and Function: Controversies and New Insights (Endocrine Reviews, 2026)
• The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation (Metabolism: Clinical and Experimental, 2024)
• Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension (Circulation, 2023)
• Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics (Circulation, 2020)
• Inclusion body myositis: update (Current Opinion in Rheumatology, 2014)
• Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments (Endocrine Reviews, 2024)
• Supplementing With Which Form of Creatine (Hydrochloride or Monohydrate) Alongside Resistance Training Can Have More Impacts on Anabolic/Catabolic Hormones, Strength and Body Composition? (Physiological Research, 2024)